Internal medicine (Tokyo, Japan) · 2018
Successful Bridging Chemotherapy with Gemcitabine, Carboplatin, and Dexamethasone before Unrelated Stem Cell Transplantation for Hepatosplenic T-cell Lymphoma.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Okuni Marika, Yakushijin Kimikazu, Uehara Keiichiro, Ichikawa Hiroya, Suto Hirotaka, Hashimoto Akiko, Tanaka Yasuhiro, Shinzato Isaku, Sakai Rina, Mizutani Yu, Nagao Shigeki, Kurata Keiji, Kakiuchi Seiji, Miyata Yoshiharu, Inui Yumiko, Saito Yasuyuki, Kawamoto Shinichiro, Yamamoto Katsuya, Ito Mitsuhiro, Matsuoka Hiroshi, Minami Hironobu
Аннотация
A 45-year-old woman was diagnosed with hepatosplenic T-cell lymphoma (HSTCL), a rare subtype of peripheral T-cell lymphoma. She received different types of chemotherapy, but disease progression was observed. To reduce the tumor burden before an unrelated bone marrow transplantation, combination chemotherapy consisting of the gemcitabine, carboplatin, and dexamethasone (GCD) was administered as bridging therapy, resulting in a reduction in the number of lymphoma cells. We were then able to perform bone marrow transplantation. Although she experienced some adverse events, she successfully achieved long-term remission. We herein report a successful case of HSTCL treated with unrelated stem cell transplantation following the GCD regimen as bridging chemotherapy.